AKTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Akari Therapeutics, Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$0.90 |
| Beta | 0.79 |
| 1 Month Change | 30.61% |
| 3 Month Change | -52.59% |
| 1 Year Change | -55.56% |
| 3 Year Change | -95.59% |
| 5 Year Change | -96.70% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Akari Therapeutics GAAP EPS of $0.00
Sep 27Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Sep 20
Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment
Jul 28Akari Therapeutics GAAP EPS of $0.00
Jul 20Patient completes course with Akari's stem cell transplant related complication treatment
Jul 07We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate
Dec 31Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan
Apr 28Akari Therapeutics reports FY results
Apr 21We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
Mar 15Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?
Jan 21Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares
Dec 17Akari Therapeutics updates trial progress; returns to profitability
Dec 11Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease
Dec 03Shareholder Returns
| AKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -0.1% | -0.5% |
| 1Y | -55.6% | -6.4% | 23.2% |
Return vs Industry: AKTX underperformed the US Biotechs industry which returned -7% over the past year.
Return vs Market: AKTX underperformed the US Market which returned 23% over the past year.
Price Volatility
| AKTX volatility | |
|---|---|
| AKTX Average Weekly Movement | 18.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AKTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKTX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Samir Patel | www.akaritx.com |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
Akari Therapeutics, Plc Fundamentals Summary
| AKTX fundamental statistics | |
|---|---|
| Market cap | US$31.69m |
| Earnings (TTM) | -US$20.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs AKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.16m |
| Earnings | -US$20.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -14.9% |
How did AKTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 13:59 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |